{"entity":{"id":"actm-838","kind":"drug","name":"ACTM-838","aka":[],"tldr":"ACTM-838 is an experimental engineered attenuated Salmonella Typhimurium from Actym Therapeutics, in phase 1 trials for advanced solid tumours; its current status is not stated.","summary":"ACTM-838 is an engineered attenuated Salmonella Typhimurium (bacterial delivery, STACT platform) from Actym Therapeutics. An engineered, weakened Salmonella given into a vein that gathers in tumours and delivers two immune payloads there: an engineered IL-15 complex and a constitutively active STING. Its furthest stage is phase 1, for advanced solid tumours. ClinicalTrials.gov registers it in one study linked below. Registry lists NCT06336148 as terminated: \"Sponsor's strategic business decision\". The company website still says ACTM-838 \"is currently in a Phase 1a/b trial\". Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Actym Therapeutics: actymthera.com","url":"https://www.actymthera.com/pipeline"},{"label":"Actym Therapeutics: synapse.patsnap.com","url":"https://synapse.patsnap.com/article/actym-gets-ind-clearance-for-phase-1-trial-of-actm-838-in-solid-tumor-patients"},{"label":"Actym Therapeutics: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT06336148"},{"label":"ClinicalTrials.gov: trials of ACTM-838","url":"https://clinicaltrials.gov/search?intr=ACTM-838"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["actym-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06336148"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"ACTM-838","modality":"Engineered attenuated Salmonella Typhimurium (bacterial delivery, STACT platform)","mechanism":"An engineered, weakened Salmonella given into a vein that gathers in tumours and delivers two immune payloads there: an engineered IL-15 complex and a constitutively active STING.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/actm-838/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"actym-therapeutics","kind":"company","name":"Actym Therapeutics","route":"/companies/actym-therapeutics/"}],"trial":[{"id":"nct06336148","kind":"trial","name":"A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors","route":"/trials/nct06336148/"}]}}